Short Interest in InflaRx (NASDAQ:IFRX) Decreases By 13.7%

InflaRx (NASDAQ:IFRX) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 415,200 shares, a decline of 13.7% from the January 15th total of 481,300 shares. Based on an average daily trading volume, of 305,500 shares, the short-interest ratio is currently 1.4 days.

Hedge Funds Weigh In On InflaRx

A number of hedge funds have recently bought and sold shares of the company. Two Sigma Securities LLC bought a new stake in InflaRx during the 4th quarter valued at about $28,000. Walleye Capital LLC bought a new position in shares of InflaRx in the fourth quarter worth approximately $51,000. Geode Capital Management LLC grew its holdings in shares of InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after buying an additional 11,900 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of InflaRx by 20.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock valued at $275,000 after acquiring an additional 19,000 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in InflaRx in the 4th quarter worth approximately $1,576,000. Institutional investors own 42.39% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of InflaRx in a report on Thursday, January 16th.

InflaRx Stock Performance

Shares of IFRX stock traded down $0.70 during mid-day trading on Friday, reaching $2.00. 4,566,637 shares of the company’s stock traded hands, compared to its average volume of 193,817. InflaRx has a 12 month low of $1.16 and a 12 month high of $2.82. The company’s 50-day moving average price is $2.42 and its 200-day moving average price is $1.91.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.